Cardiovascular and safety outcomes of SGLT2i in patients with heart failure undergoing dialysis




María A. Mesa-Maya, Servicio de Cardiología, Clínica CES, Medellín, Colombia
Juan J. Hurtado-Guerra, Servicio de Cardiología, Centro Cardiovascular Somer Incare, Rionegro, Colombia
Tomás Echavarría-Bayter, Datatrooper, Medellín, Colombia
María J. Baena-Duque, Facultad de Medicina, Universidad CES, Medellín, Colombia
Valeria López-Cardona, Facultad de Medicina, Universidad Cooperativa de Colombia, Medellín, Colombia
Elsa M. Vásquez-Trespalacios, División de Posgrados Clínicos, Facultad de Medicina, Universidad CES, Medellín, Colombia
Néstor A. López-Pompey, Servicio de Endocrinología, City Médica, Rionegro, Colombia
Laura Duque-González, Servicio de Cardiología PUL.SOS, Medellín, Colombia


Introduction: Heart failure is a significant complication in patients with advanced chronic kidney disease. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown benefits in renal function and cardiovascular events in this population, but their use in dialysis remains poorly studied. Objective: To evaluate the effect of SGLT2 inhibitors in heart failure patients on dialysis by analyzing their impact on left ventricular ejection fraction (LVEF), NYHA functional class, hospitalization, and mortality. Methods: This was a retrospective cohort study in heart failure patients on dialysis at a Colombian hospital. A total of 15 patients were included; 13 completed follow-up, one died, and another was lost during the study period. Results: LVEF increased a mean of 12.99 percentage points, from 37.9% to 51.0%. At baseline, 66.7% had an LVEF ≤ 40%; at follow-up, 100% had recovered an LVEF > 40%. An average 1.68 kg weight loss was also recorded. One patient (6.7%) died, and two hospitalizations occurred, with no serious adverse events reported. Conclusions: SGLT2 inhibitor use in heart failure patients on dialysis showed a trend toward improving cardiac function without increasing adverse events. Larger studies are needed to confirm these findings.



Keywords: Heart failure. Chronic kidney disease. Dialysis. SGLT2 inhibitors. Ejection fraction.